2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2020
Reentry Interventions That Address Substance Use: A Systematic Review
Moore KE, Hacker RL, Oberleitner L, McKee SA. Reentry Interventions That Address Substance Use: A Systematic Review. Psychological Services 2020, 17: 93-101. PMID: 30307269, PMCID: PMC6459737, DOI: 10.1037/ser0000293.Peer-Reviewed Original ResearchConceptsEvidence-based treatmentsReentry interventionsSubstance useCognitive behavioral therapyParticular treatment approachSubstance use outcomesReduced substance useSubstance use problemsJustice-involved individualsReduced recidivismMotivational interviewingAddress substance useRecidivism outcomesUse problemsUse outcomesTreatment groupsSystematic reviewTherapeutic communityUnique interventionsRisk of relapseMonths of releaseRecidivismFull-text articles